PBYI Quote, Financials, Valuation and Earnings

Nephros, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 7.07%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Nephros, Inc.'s return on equity of 16.22%.

Puma Biotechnology, Inc. has a consensus price target of $5.00, signalling downside risk potential of -25.15%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 72.41%. Given that Nephros, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Nephros, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.221, which suggesting that the stock is 22.056% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.715%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Nephros, Inc.'s net income of $337K. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.02x while Nephros, Inc.'s PE ratio is 27.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.58x versus 2.26x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -9.34%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Pfizer Inc.'s return on equity of 10.84%.

Puma Biotechnology, Inc. has a consensus price target of $5.00, signalling downside risk potential of -25.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 4.9%. Given that Pfizer Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Pfizer Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.221, which suggesting that the stock is 22.056% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.28% to investors and pays a quarterly dividend of $0.43 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.02x while Pfizer Inc.'s PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.58x versus 2.49x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 40.17%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Puma Biotechnology, Inc. has a consensus price target of $5.00, signalling downside risk potential of -25.15%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 44.46%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.221, which suggesting that the stock is 22.056% more volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Puma Biotechnology, Inc.'s net income of $8.8M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.02x while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.58x versus 2.33x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -246.76%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

Puma Biotechnology, Inc. has a consensus price target of $5.00, signalling downside risk potential of -25.15%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 125.95%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..

Puma Biotechnology, Inc. has a beta of 1.221, which suggesting that the stock is 22.056% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.622, suggesting its less volatile than the S&P 500 by 37.837%.

Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.02x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.58x versus 1.64x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.